Literature DB >> 35621713

Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade.

Wei Wang1, Taja Lozar1,2, Athena E Golfinos1, Denis Lee1, Ellery Gronski1, Ella Ward-Shaw1, Mitchell Hayes1, Justine Y Bruce3,4, Randall J Kimple4,5, Rong Hu4,6, Paul M Harari4,5, Jin Xu6, Aysenur Keske6, Paul M Sondel4,5, Megan B Fitzpatrick6, Huy Q Dinh1,4,7, Paul F Lambert1,4.   

Abstract

PURPOSE: We investigated whether in human head and neck squamous cell carcinoma (HNSCC) high levels of expression of stress keratin 17 (K17) are associated with poor survival and resistance to immunotherapy. EXPERIMENTAL
DESIGN: We investigated the role of K17 in regulating both the tumor microenvironment and immune responsiveness of HNSCC using a syngeneic mouse HNSCC model, MOC2. MOC2 gives rise to immunologically cold tumors that are resistant to immune-checkpoint blockade (ICB). We engineered multiple, independent K17 knockout (KO) MOC2 cell lines and monitored their growth and response to ICB. We also measured K17 expression in human HNSCC of patients undergoing ICB.
RESULTS: MOC2 tumors were found to express K17 at high levels. When knocked out for K17 (K17KO MOC2), these cells formed tumors that grew slowly or spontaneously regressed and had a high CD8+ T-cell infiltrate in immunocompetent syngeneic C57BL/6 mice compared with parental MOC2 tumors. This phenotype was reversed when we depleted mice for T cells. Whereas parental MOC2 tumors were resistant to ICB treatment, K17KO MOC2 tumors that did not spontaneously regress were eliminated upon ICB treatment. In a cohort of patients with HNSCC receiving pembrolizumab, high K17 expression correlated with poor response. Single-cell RNA-sequencing analysis revealed broad differences in the immune landscape of K17KO MOC2 tumors compared with parental MOC2 tumors, including differences in multiple lymphoid and myeloid cell types.
CONCLUSIONS: We demonstrate that K17 expression in HNSCC contributes to immune evasion and resistance to ICB treatment by broadly altering immune landscapes of tumors. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35621713      PMCID: PMC9250640          DOI: 10.1158/1078-0432.CCR-21-3039

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   13.801


  51 in total

1.  Elevated expression of keratin 17 in oropharyngeal squamous cell carcinoma is associated with decreased survival.

Authors:  Elliot Regenbogen; Michelle Mo; Jamie Romeiser; A Laurie W Shroyer; Luisa F Escobar-Hoyos; Stephanie Burke; Kenneth R Shroyer
Journal:  Head Neck       Date:  2018-04-06       Impact factor: 3.147

2.  ERK1/2 regulation of CD44 modulates oral cancer aggressiveness.

Authors:  Nancy P Judd; Ashley E Winkler; Oihana Murillo-Sauca; Joshua J Brotman; Jonathan H Law; James S Lewis; Gavin P Dunn; Jack D Bui; John B Sunwoo; Ravindra Uppaluri
Journal:  Cancer Res       Date:  2011-11-15       Impact factor: 12.701

3.  Keratin 17 expression in the hard epithelial context of the hair and nail, and its relevance for the pachyonychia congenita phenotype.

Authors:  K M McGowan; P A Coulombe
Journal:  J Invest Dermatol       Date:  2000-06       Impact factor: 8.551

4.  A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer.

Authors:  Ayse Bassez; Hanne Vos; Laurien Van Dyck; Giuseppe Floris; Ingrid Arijs; Christine Desmedt; Bram Boeckx; Marlies Vanden Bempt; Ines Nevelsteen; Kathleen Lambein; Kevin Punie; Patrick Neven; Abhishek D Garg; Hans Wildiers; Junbin Qian; Ann Smeets; Diether Lambrechts
Journal:  Nat Med       Date:  2021-05-06       Impact factor: 53.440

5.  Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin.

Authors:  Daryle Depianto; Michelle L Kerns; Andrzej A Dlugosz; Pierre A Coulombe
Journal:  Nat Genet       Date:  2010-09-26       Impact factor: 38.330

6.  Regulation of epidermal expression of keratin K17 in inflammatory skin diseases.

Authors:  M Komine; I M Freedberg; M Blumenberg
Journal:  J Invest Dermatol       Date:  1996-10       Impact factor: 8.551

7.  Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

Authors:  Ranee Mehra; Tanguy Y Seiwert; Shilpa Gupta; Jared Weiss; Iris Gluck; Joseph P Eder; Barbara Burtness; Makoto Tahara; Bhumsuk Keam; Hyunseok Kang; Kei Muro; Ravit Geva; Hyun Cheol Chung; Chia-Chi Lin; Deepti Aurora-Garg; Archana Ray; Kumudu Pathiraja; Jonathan Cheng; Laura Q M Chow; Robert Haddad
Journal:  Br J Cancer       Date:  2018-06-29       Impact factor: 7.640

8.  Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor.

Authors:  Joseph E Grossman; Divya Vasudevan; Cailin E Joyce; Manuel Hildago
Journal:  Oncogene       Date:  2021-01-26       Impact factor: 9.867

9.  The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote.

Authors:  Yang Liao; Gordon K Smyth; Wei Shi
Journal:  Nucleic Acids Res       Date:  2013-04-04       Impact factor: 16.971

10.  Keratin 17 Is Induced in Oral Cancer and Facilitates Tumor Growth.

Authors:  Rumana Khanom; Chi Thi Kim Nguyen; Kou Kayamori; Xin Zhao; Keiichi Morita; Yoshio Miki; Ken-Ichi Katsube; Akira Yamaguchi; Kei Sakamoto
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.